LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio sat down with new Member Remilk, to learn more about the future of sustainable food production

22/02/2022
INTERVIEW

Aviv Wolff

Aviv Wolff, Co-Founder and CEO of Remilk, has extensive experience in managing complex operation systems as well as recruiting, training, and leading teams. An innovative entrepreneur, Aviv is the mind behind several social and business initiatives. He is the recipient of multiple innovation awards and recognitions.

Interview with... Aviv Wolff, Co-Founder and CEO at Remilk

1) What inspired the foundation of Remilk?
After founding a cyber-security company, I realized that’s not where my passion lies. I knew I wanted to be part of something truly big that will generate real, positive change in the world we live in. At the time I was traveling and walked into a restaurant that was serving one of the earliest versions of today’s leading non-animal burgers. I was blown away by the taste and texture and that’s when I knew what my next project will be: creating real dairy that is kinder, greener, healthier, and just as importantly - delicious and affordable.

2) What potential do you see in demand for lab-cultured milk?
We know from research and from conversations with companies around the world that demand for animal-free, sustainable dairy options is constantly growing. Our dairy’s production method results in products that don’t require consumers to adapt to new flavors and textures, providing them with the same dairy experience they love, without its downsides. It also makes traditional-tasting dairy available to over 65% of the world’s population who suffer from lactose intolerance. In that sense, Remilk offers a solution not only for niche audiences but for everyone, so its potential is as big as the size of the entire dairy market!

3) What are your plans for growth?
We are in constant growth, with our team growing by more than 685% in 2021. Our latest oversubscribed funding round yielded $120M, which is dedicated to scaling up our production in several facilities around the world.

4) How do you see Remilk being able to transform the milk industry's impact on climate change and animal welfare?
We are lucky to be able to say we’re taking cows entirely out of the equation. Not one animal cell is used in our production process, ending cows’ historical role as dairy providers for humankind. Abandoning our dependence on animals also means we are drastically cutting down on the precious resources used by the traditional industry such as habitable land, water and energy. Dairy produced via microbial fermentation emits a fraction of the harmful GHG emissions compared to its traditional counterpart, so we see ourselves as proudly standing in the forefront of the fight to dramatically reduce the food industry’s devastating impact on our planet.

Interview with Remilk


Download
2022_02_G_I_Interview-with-RemilkDownload
Share
Communications Team
Communications Team

Related posts

12/11/2025

EuropaBio response to the EU Biotech Act public consultation


Read more
05/11/2025

EuropaBio recommendations for the Circular Economy Act


Read more
31/10/2025

Healthcare Associations warn of risks from PFAS restriction approach  – failure to assess the impact on the availability of human and animal medicines


Read more

Important links

  • EuropaBio response to the EU Biotech Act public consultation
  • EuropaBio recommendations for the Circular Economy Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.